Xylitol acts as an anticancer monosaccharide to induce selective cancer death via regulation of the glutathione level.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory study involving in vitro cell assays and an in vivo mouse model.
PubMed 32275922 · doi:10.1016/j.cbi.2020.109085
What was done
Researchers investigated the molecular mechanism of xylitol-induced cancer cell death in vitro and evaluated its tumor-suppressing effects in vivo using intravenous administration in mice. They examined the roles of the glutathione-degrading enzyme CHAC1, endoplasmic reticulum (ER) stress, oxidative stress, and the capacity of xylitol to sensitize cancer cells to chemotherapeutic drugs.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. Directionally, xylitol induced the expression of CHAC1, which was required for ER stress and secondary oxidative stress, leading to apoptotic death in cancer cells. Intravenous xylitol suppressed tumor growth in mice via ER stress pathways and sensitized cancer cells to chemotherapeutic drugs.
Why it matters
This paper identifies a specific molecular mechanism (CHAC1 induction and glutathione depletion) by which xylitol exerts cancer-selective cytotoxicity, suggesting a potential role as an adjunct to chemotherapy.
Limits
The abstract reports no quantitative data, sample sizes, specific cancer types, or drug dosages. All findings are restricted to in vitro and mouse models and cannot be directly translated to human clinical efficacy or safety.
Cited by
- context Studies demonstrate that xylitol is beneficial for patients undergoing chemotherapy.